Table 2. Dose-response relationships for individual drugs included in the analyses.

Information Reported	Rofecoxib		Celecoxib		Ibuprofen		Naproxen		Diclofenac
	≤25 mg/d	>25 mg/d	≤200 mg/d	>200 mg/d	Low	High	Low	High	Low	High
Overall summary estimates	1.37	2.17	1.26	1.69	1.05	1.78	0.97	1.05	1.22	1.98
95% CI	1.20, 1.57	1.59, 2.97	1.09, 1.47	1.11, 2.57	0.96, 1.15	1.35, 2.34	0.87, 1.08	0.89, 1.24	1.12, 1.33	1.40, 2.82
p-Value for dose effect	0.008		0.197		0.0004		0.433		0.009
Studies contributing dose data	16 of 34 studies reporting on rofecoxib		11 of 35 studies reporting on celecoxib		11 of 38 studies reporting on ibuprofen		10 of 41 studies reporting on naproxen		10 of 29 studies reporting on diclofenac
Heterogeneity Cochrane Q	71.8	80.7	33.7	119.9	43.3	221.4	11.7	29.4	16.3	437.5
p-Value	<0.0001	<0.0001	0.0008	<0.0001	<0.0001	<0.0001	0.4	0.0058	0.1786	<0.0001

The RR values in this table differ from those in Table 1 because only a sub-set of all available studies reported dose-response relationships. “Low” and “high” daily doses of ibuprofen, naproxen, and diclofenac were defined in the individual studies as follows. Ibuprofen low dose/high dose: eight studies, ≤1,200 mg/>1,200 mg; one study, ≤1,600 mg/>1,600 mg; two studies, <1,800 mg/≥1,800 mg. Naproxen low dose/high dose: two studies, ≤500 mg/>500 mg; four studies, ≤750 mg/>750 mg; four studies, ≤1,000 mg/≥1,000 mg. Diclofenac low dose/high dose: six studies, ≤100 mg/>100 mg; two, studies <100 mg/≥100 mg; two studies, <150 mg/≥150 mg.